ArticleCommunications medicine2025
Forecasting the diabetic retinopathy progression using generative adversarial networks.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A panoramic perspective: application prospects and outlook of multimodal artificial intelligence in the management of diabetic retinopathy.Frontiers in public health · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic retinopathy (DR) is the leading cause of blindness worldwide, making early prediction of DR progression crucial for effectively preventing visual loss. This study introduces a prediction framework DRForecastGAN (Diabetic Retinopathy Forecast Generative Adversarial Network), and investigates its clinical value in predicting DR development.
methodsDRForecastGAN model, consisting of a generator, discriminator, and registration network, was trained, validated, and tested in training (12,852 images), internal validation (2734 images), and external test (8523 images) datasets. A pre-trained ResNet50 classification model identified the DR severity on synthetic images. The performance of the proposed DRForecastGAN model was compared with the CycleGAN and Pix2Pix models in image reality and DR severity of the synthesized fundus images by calculating Fréchet Inception Distance (FID), Peak Signal-to-Noise Ratio (PSNR), Structural Similarity Index (SSIM), and area under the curve (AUC).
resultsDRForecastGAN model has the lowest FID, highest PSNR and highest SSIM on internal validation (FID: 27.3 vs. 32.8 vs. 34.4; PSNR: 25.3 vs. 17.0 vs. 16.9; SSIM: 0.93 vs. 0.79 vs. 0.65) and external test (FID: 37.6 vs.45.1 vs.48.4; PSNR: 20.7 vs.15.2 vs.14.7; SSIM: 0.86 vs.0.69 vs.0.63) datasets compared with Pix2Pix and CycleGAN models. In the prediction of DR severity, our DRForecastGAN model outperforms both Pix2Pix and CycleGAN models, achieving the highest AUC values on both internal validation (0.87 vs. 0.76 vs. 0.75) and external test (0.85 vs. 0.70 vs. 0.69) datasets.
conclusionsThe proposed DRForecastGAN model can effectively visualize DR development by synthesizing future fundus images, offering potential utility for both treatment and ongoing monitoring of DR.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.